Cancer: Delcath lands expanded CE Mark for organ-isolating chemo treatment

Delcath logo

Delcath Systems (NSDQ:DCTH) won expanded CE Mark approval in the European Union for its ChemoSat organ-isolating cancer treatment system, landing indication for a new drug used to target liver tumors.

The E.U. regulatory approval allows Delcath to market ChemoSat for use with doxorubicin hydrochloride, an established chemotherapy agent commonly used to treat hepatocellular carcinoma, the most common primarily malignant liver tumor.

"Doxorubicin is a drug widely used to treat HCC in Asia, which is where we see the market opportunity for our ChemoSat system with doxorubicin injection," president & CEO Eamonn Hobbs said in prepared remarks. "Based upon prior discussions, several potential strategic partners in Asia have indicated that they believe that our ChemoSat system with doxorubicin may be well received by the medical community in the region."

Having the expanded CE Mark in hand may help the company establish new partnerships in Asia, where more than 550,000 new cases of HCC are diagnosed each year, Hobbs added. The median length of survival for a patient in the intermediate stage of HCC is less than 11 months, he said.

Delcath must still overcome regulatory hurdles specific to China in order to penetrate that market, including conducting local clinical trials in order to obtain approval by the China State Food & Drug Administration, according to a press release.

The New York-based device maker plans to pursue ChemoSat approvals in key Asian markets such as China and Korea, but "does not intend to market ChemoSat with doxorubicin injection in the European Economic Area at this time," according to the statement.

The win is more good news for Delcath, which last week announced that the FDA had accepted for review its 2nd new drug application, bringing the device maker 1 step closer to reaching the U.S. market.

Delcath’s ChemoSat uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ from the rest of the body’s bloodstream.

Check out our interview with Delcath president & CEO Eamonn Hobbs from June, 2011.

Earlier this year Delcath sold its 1st commercial unit of the ChemoSat system to the European Institute of Oncology, marking the company’s transition from a research & development stage company to a commercial enterprise.

Delcath has had a rough go with the ChemoSat system in the last couple years, with inconclusive trial results and a $5 million share stock offering that didn’t win much favor from The Street.

The troubles began when the FDA refused the company’s new drug application over concerns that the information provided was insufficient for review. ChemoSat is regulated as a medical device in Europe, where it won CE Mark approval in April 2011, but as far as the FDA is concerned it is regulated as drug-device combination that also requires new drug labeling.

"The CE Mark that we have in Europe is a very important regulatory approval, because virtually every country in the world outside of the U.S. accepts the CE Mark as a predicate regulatory approval and provides reciprocal approval," Hobbs told in an exclusive interview in June 2011. "We’ll be leveraging the CE Mark around the world to gain regulatory approval in all the emerging markets in relatively short order. We expect to have regulatory approval in countries in Asia, South America, Central America and Canada, the Middle East and Africa starting in 2012. We should have regulatory approval in virtually all the countries by the end of 2013."

RSS From Medical Design & Outsourcing

  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]
  • MasterControl’s CEO talks EQMS software and new partnerships
    MasterControl offers a quality and compliance software that helps device companies speed time to market and improve their bottom lines. Under Jon’s leadership, the company has blossomed into a market leader and has a unique corporate culture that fosters growth, excellence and quality. In this podcast, MasterControl’s CEO, Jon Beckstrand, will discuss electronic quality management […]
  • BIT Group launches white label IVD solutions
    BIT Group has launched a product line of customizable IVD white label instruments. During recent years, BIT has invested capital and resources developing customizable, ready-to-use IVD systems to address a growing demand. “The IVD market is challenging for our clients,” said Marius Balger, CEO at BIT. “OEM’s must adhere to a growing number of evolving IVD […]
  • Toshiba expands line-up of ARM Cortex-M-based microcontrollers
    Toshiba announced that it has enhanced its current “TX Family” of ARM core-based microcontrollers and started to develop three series of microcontrollers, “TXZ0 series,” “TXZ3 series” and “TXZ4 series,” as part of the “TXZTM Family.” The TXZTM Family is a new collection of flash microcontrollers that support low-power consumption and high-speed operation for IoT and M2M […]
  • Parker Hannifin consolidates, layoffs ahead
    Parker Hannifin plans to consolidate a number of internal divisions, close 2 facilities and expand its Mexican operations, according to an internally distributed letter from Andy Ross, Parker’s engineered materials group president. The company has confirmed the letter was authentic, but has not disclosed how many employees will be affected by the new plans or […]
  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]

Leave a Reply